MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.

In acute myeloid leukemia (AML), chemotherapy resistance remains prevalent and poorly understood. Using functional proteomics of patient AML specimens, we identified MEF2C S222 phosphorylation as a specific marker of primary chemoresistance. We found that Mef2cS222A/S222A knock-in mutant mice engineered to block MEF2C phosphorylation exhibited normal hematopoiesis, but were resistant to leukemogenesis induced by MLL-AF9 MEF2C phosphorylation was required for leukemia stem cell maintenance and induced by MARK kinases in cells. Treatment with the selective MARK/SIK inhibitor MRT199665 caused apoptosis and conferred chemosensitivity in MEF2C-activated human AML cell lines and primary patient specimens, but not those lacking MEF2C phosphorylation. These findings identify kinase-dependent dysregulation of transcription factor control as a determinant of therapy response in AML, with immediate potential for improved diagnosis and therapy for this disease.Significance: Functional proteomics identifies phosphorylation of MEF2C in the majority of primary chemotherapy-resistant AML. Kinase-dependent dysregulation of this transcription factor confers susceptibility to MARK/SIK kinase inhibition in preclinical models, substantiating its clinical investigation for improved diagnosis and therapy of AML. Cancer Discov; 8(4); 478-97. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 371.

[1]  N. López-Bigas,et al.  HDAC7 Is a Repressor of Myeloid Genes Whose Downregulation Is Required for Transdifferentiation of Pre-B Cells into Macrophages , 2013, PLoS genetics.

[2]  Yi Zhang,et al.  multiplierz: an extensible API based desktop environment for proteomics data analysis , 2009, BMC Bioinformatics.

[3]  J. Dick,et al.  Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity , 2004, Nature Immunology.

[4]  E. Cho,et al.  Menin represses JunD transcriptional activity in protein kinase Cθ-mediated Nur77 expression , 2005, Experimental & Molecular Medicine.

[5]  A. Letai,et al.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.

[6]  Christopher A. Miller,et al.  Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. , 2015, JAMA.

[7]  M. Imoto,et al.  GSK-3β Directly Phosphorylates and Activates MARK2/PAR-1* , 2005, Journal of Biological Chemistry.

[8]  A. D. Dei Tos,et al.  The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness , 2017, PLoS genetics.

[9]  E. Lam,et al.  Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells , 2005, Oncogene.

[10]  M. Marra,et al.  MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation , 2015, Nature Communications.

[11]  S. Ficarro,et al.  Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment. , 2009, Analytical chemistry.

[12]  A. Kentsis,et al.  High Sensitivity Quantitative Proteomics Using Automated Multidimensional Nano-flow Chromatography and Accumulated Ion Monitoring on Quadrupole-Orbitrap-Linear Ion Trap Mass Spectrometer* , 2017, Molecular & Cellular Proteomics.

[13]  R. Pieters,et al.  NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. , 2011, Blood.

[14]  D. Jd,et al.  Pediatric AML: From Biology to Clinical Management , 2015 .

[15]  Mark D'Ascenzo,et al.  8‐Plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease , 2007, Proteomics.

[16]  F. Sablitzky,et al.  The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. , 2006, Blood.

[17]  B. Nadal-Ginard,et al.  Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. , 1992, Genes & development.

[18]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[19]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[20]  J. Dick,et al.  Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia , 2005, Leukemia.

[21]  S. Raimondi,et al.  High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group , 2015, Journal of Hematology & Oncology.

[22]  D. Small,et al.  Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. , 2004, Leukemia research.

[23]  N. Copeland,et al.  Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. , 2005, Blood.

[24]  J. Downing,et al.  Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.

[25]  Cell Lines , 1992, Spermatogenesis.

[26]  R. Pieters,et al.  Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements , 2012, Haematologica.

[27]  N. Gray,et al.  Protected Amine Labels: A Versatile Molecular Scaffold for Multiplexed Nominal Mass and Sub-Da Isotopologue Quantitative Proteomic Reagents , 2014, Journal of The American Society for Mass Spectrometry.

[28]  M. Cleary,et al.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.

[29]  Bob Löwenberg,et al.  Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  John N. Hutchinson,et al.  Phosphoproteomic profiling of mouse primary HSPCs reveals new regulators of HSPC mobilization. , 2016, Blood.

[31]  R. Arceci,et al.  Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing. , 2013, Seminars in hematology.

[32]  Wolfgang Wurst,et al.  Generation of targeted mouse mutants by embryo microinjection of TALENs. , 2014, Methods.

[33]  B. Leber,et al.  The sonic hedgehog factor Gli1 imparts drug resistance through inducible glucuronidation , 2014, Nature.

[34]  H. Jäck,et al.  Essential control of early B-cell development by Mef2 transcription factors. , 2016, Blood.

[35]  Zhenguo Wu,et al.  Myocyte Enhancer Factor 2 Acetylation by p300 Enhances Its DNA Binding Activity, Transcriptional Activity, and Myogenic Differentiation , 2005, Molecular and Cellular Biology.

[36]  Patrick G. A. Pedrioli,et al.  Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages , 2012, Proceedings of the National Academy of Sciences.

[37]  M. Hornsveld,et al.  Restraining FOXO3-dependent transcriptional BMF activation underpins tumour growth and metastasis of E-cadherin-negative breast cancer , 2016, Cell Death and Differentiation.

[38]  Jiahuai Han,et al.  Regulation of the MEF2 Family of Transcription Factors by p38 , 1999, Molecular and Cellular Biology.

[39]  M. Peng,et al.  Toward a comprehensive characterization of a human cancer cell phosphoproteome. , 2013, Journal of proteome research.

[40]  Guido Marcucci,et al.  Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia , 2016, Nature Communications.

[41]  C. Zwaan,et al.  Pediatric AML: From Biology to Clinical Management , 2015, Journal of clinical medicine.

[42]  N. Borcherding,et al.  Stabilization of NF-κB-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia , 2018, Cell reports.

[43]  K. Kemphues,et al.  par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed , 1995, Cell.

[44]  G. Brittinger,et al.  In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. , 1998, Experimental hematology.

[45]  E. Olson,et al.  Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Martín,et al.  Mutational analysis of the DNA binding, dimerization, and transcriptional activation domains of MEF2C , 1996, Molecular and cellular biology.

[47]  E. Olson,et al.  MEF2: a calcium-dependent regulator of cell division, differentiation and death. , 2002, Trends in biochemical sciences.

[48]  C. Brancolini,et al.  The Control Operated by the Cell Cycle Machinery on MEF2 Stability Contributes to the Downregulation of CDKN1A and Entry into S Phase , 2015, Molecular and Cellular Biology.

[49]  C. Bach,et al.  Leukemogenic transformation by HOXA cluster genes. , 2010, Blood.

[50]  S. T. Kim,et al.  Menin represses JunD transcriptional activity in protein kinase C theta-mediated Nur77 expression. , 2005, Experimental & molecular medicine.

[51]  R. Battini,et al.  Phosphorylation-dependent degradation of MEF2C contributes to regulate G2/M transition , 2015, Cell cycle.

[52]  Unnur Thorsteinsdottir,et al.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b , 1998, The EMBO journal.

[53]  Jeffrey D. Zaremba,et al.  Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo , 2008, Proceedings of the National Academy of Sciences.

[54]  M. Andreeff,et al.  Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang , 2016, Cancer biology & medicine.

[55]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[56]  E. Olson,et al.  The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. , 2008, Blood.

[57]  Y. Ishihama,et al.  Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. , 2012, Journal of biochemistry.

[58]  Francine E. Garrett-Bakelman,et al.  DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling , 2016, Nature Medicine.

[59]  Hongtao Yu,et al.  Phosphorylation-facilitated sumoylation of MEF2C negatively regulates its transcriptional activity , 2006, BMC Biochemistry.

[60]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. Byrd,et al.  Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia , 2017, British journal of haematology.

[62]  F. Camargo,et al.  Regulation of lymphoid versus myeloid fate 'choice' by the transcription factor Mef2c , 2009, Nature Immunology.

[63]  Andrew L. Kung,et al.  Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia , 2012, Nature Medicine.

[64]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[65]  E. Olson,et al.  Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. , 2009, Blood.

[66]  B. Chait,et al.  Helicobacter pylori CagA Inhibits PAR1/MARK Family Kinases by Mimicking Host Substrates , 2009, Nature Structural &Molecular Biology.

[67]  Andrew M Haidle,et al.  MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation. , 2017, Bioorganic & medicinal chemistry letters.

[68]  E. Mandelkow,et al.  Glycogen Synthase Kinase (GSK) 3β Directly Phosphorylates Serine 212 in the Regulatory Loop and Inhibits Microtubule Affinity-regulating Kinase (MARK) 2* , 2008, Journal of Biological Chemistry.

[69]  H. Drexler,et al.  MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines , 2008, Leukemia.

[70]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[71]  P. Romanienko,et al.  A Vector with a Single Promoter for In Vitro Transcription and Mammalian Cell Expression of CRISPR gRNAs , 2016, PloS one.

[72]  S. Miyano,et al.  Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients , 2014, Leukemia.

[73]  A. Villunger,et al.  Bim and Bmf in tissue homeostasis and malignant disease , 2008, Oncogene.

[74]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[75]  Jeffrey A. Magee,et al.  Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations , 2016, eLife.

[76]  W. Pierceall,et al.  BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia , 2013, Molecular Cancer Therapeutics.

[77]  G. Brittinger,et al.  In Acute Myeloid Leukemia only the Coexpression of at Least Two Proteins Including P-Glycoprotein, the Multidrug Resistance-Related Protein MRP, bcl-2, Mutant p53 and Heat-Shock Protein 27 is Predictive for the Response to Induction Chemotherapy , 1998 .

[78]  G. Shulman,et al.  Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo , 2007, Proceedings of the National Academy of Sciences.

[79]  R. Schiestl,et al.  MEF2C protects bone marrow B-lymphoid progenitors during stress haematopoiesis , 2016, Nature Communications.

[80]  R. Levine,et al.  Molecular therapy for acute myeloid leukaemia , 2016, Nature Reviews Clinical Oncology.

[81]  C. Bucana,et al.  Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. , 1997, Science.

[82]  T. Gulick,et al.  Phosphorylation and Alternative Pre-mRNA Splicing Converge To Regulate Myocyte Enhancer Factor 2C Activity , 2004, Molecular and Cellular Biology.

[83]  S. Armstrong,et al.  JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors , 2015, Genes & development.

[84]  T. Hoang,et al.  SCL, LMO1 and Notch1 Reprogram Thymocytes into Self-Renewing Cells , 2014, PLoS genetics.

[85]  Richard Benton,et al.  The Drosophila Homolog of C. elegans PAR-1 Organizes the Oocyte Cytoskeleton and Directs oskar mRNA Localization to the Posterior Pole , 2000, Cell.

[86]  T. Graeber,et al.  An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. , 2011, Genes & development.

[87]  M E Greenberg,et al.  Neuronal activity-dependent cell survival mediated by transcription factor MEF2. , 1999, Science.

[88]  James T. Webber,et al.  Online Nanoflow Multidimensional Fractionation for High Efficiency Phosphopeptide Analysis* , 2011, Molecular & Cellular Proteomics.

[89]  Fatima Al-Shahrour,et al.  In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. , 2013, Cancer cell.

[90]  D. Muzny,et al.  Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. , 2016, Cancer research.

[91]  M. Imoto,et al.  GSK-3beta directly phosphorylates and activates MARK2/PAR-1. , 2005, The Journal of biological chemistry.